Home › Funds › BENDER ROBERT & ASSOCIATES › VRTX
BENDER ROBERT & ASSOCIATES position in VRTX
VERTEX PHARMACEUTICALS INC · Health Care
BENDER ROBERT & ASSOCIATES reported holding 26,658 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$13.9M, representing 2.66% of its reported portfolio and ranking #12 among its reported holdings. BENDER ROBERT & ASSOCIATES has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How BENDER ROBERT & ASSOCIATES's VRTX position evolved
BENDER ROBERT & ASSOCIATES first disclosed a stake in VRTX in Q3 2023 at 28,454 shares (US$9.9M). The position peaked in Q3 2026 at 26,658 shares, worth US$13.9M. Across 13 filings, BENDER ROBERT & ASSOCIATES increased the stake 4 time(s), trimmed it 7 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 26,658 shares valued at US$13.9M — an increase of 355 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 28.45K | $9.89M | New |
| Q4 2023 | 28.55K | $11.62M | Hold |
| Q1 2024 | 28.17K | $11.78M | Reduce |
| Q2 2024 | 27.29K | $12.79M | Reduce |
| Q3 2024 | 27.13K | $12.62M | Reduce |
| Q4 2024 | 27.31K | $11.00M | Add |
| Q1 2025 | 27.02K | $13.10M | Reduce |
| Q2 2025 | 26.71K | $11.89M | Reduce |
| Q3 2025 | 26.33K | $10.31M | Reduce |
| Q4 2025 | 26.46K | $12.00M | Add |
| Q1 2026 | 26.17K | $11.69M | Reduce |
| Q2 2026 | 26.30K | $13.07M | Add |
| Q3 2026 | 26.66K | $13.94M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRTX and 13F data
VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRTX
- Capital World Investors 25.97M sh · $13.58B · Q3 2026
- Capital World Investors 26.12M sh · $12.97B · Q2 2026
- Capital Research Global Investors 19.49M sh · $9.68B · Q2 2026
- Capital Research Global Investors 17.81M sh · $9.31B · Q3 2026
- Invesco Ltd 8.28M sh · $4.33B · Q3 2026
- Capital International Investors 5.06M sh · $2.65B · Q3 2026
- Franklin Resources 4.46M sh · $2.45B · Q3 2026
- LOOMIS SAYLES & CO L P 3.62M sh · $1.89B · Q3 2026
- JENNISON ASSOCIATES LLC 3.00M sh · $1.49B · Q2 2026
- ALLIANCEBERNSTEIN L.P. 3.02M sh · $1.35B · Q2 2026
- VICTORY CAPITAL MANAGEMENT INC 2.56M sh · $1.34B · Q3 2026
- Janus Henderson Group 2.13M sh · $951.79M · Q1 2026
More on BENDER ROBERT & ASSOCIATES
FAQ
How long has BENDER ROBERT & ASSOCIATES held VRTX?
BENDER ROBERT & ASSOCIATES has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is BENDER ROBERT & ASSOCIATES's current position in VRTX?
As of Q3 2026, BENDER ROBERT & ASSOCIATES holds 26.66K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $13.94M, representing 2.66% of its reported portfolio and ranking #12.
Has BENDER ROBERT & ASSOCIATES been buying or selling VRTX?
In the latest 13F filing (Q3 2026), BENDER ROBERT & ASSOCIATES increased its position in VRTX. The position peaked in Q3 2026 at 26.66K shares.
Which other funds hold VRTX?
Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.